Lupin receives USFDA approval for mixed salts of a single-entity amphetamine ER capsules
The product will be manufactured at Lupin’s Somerset facility in the US
The product will be manufactured at Lupin’s Somerset facility in the US
Modernization and supply chain diversity drive new growth
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
This product will be manufactured at Lupin’s Nagpur facility in India
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Subscribe To Our Newsletter & Stay Updated